IQVIA Holdings Inc. (NYSE:IQV) Shares Sold by MGO One Seven LLC

MGO One Seven LLC trimmed its position in IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 41.9% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 2,943 shares of the medical research company's stock after selling 2,119 shares during the quarter. MGO One Seven LLC's holdings in IQVIA were worth $578,000 as of its most recent SEC filing.

Other hedge funds have also made changes to their positions in the company. Synergy Asset Management LLC acquired a new stake in IQVIA during the fourth quarter worth $33,000. GKV Capital Management Co. Inc. purchased a new stake in IQVIA in the 4th quarter valued at about $39,000. Lee Danner & Bass Inc. acquired a new position in IQVIA in the fourth quarter valued at about $44,000. Zions Bancorporation N.A. boosted its stake in IQVIA by 55.2% during the fourth quarter. Zions Bancorporation N.A. now owns 239 shares of the medical research company's stock worth $47,000 after buying an additional 85 shares during the period. Finally, Versant Capital Management Inc increased its position in shares of IQVIA by 46.0% during the fourth quarter. Versant Capital Management Inc now owns 295 shares of the medical research company's stock valued at $58,000 after acquiring an additional 93 shares during the last quarter. Hedge funds and other institutional investors own 89.62% of the company's stock.

IQVIA Price Performance

Shares of IQV stock traded up $2.32 during trading hours on Friday, hitting $153.42. The company's stock had a trading volume of 1,402,461 shares, compared to its average volume of 1,436,227. The company has a current ratio of 0.84, a quick ratio of 0.84 and a debt-to-equity ratio of 2.12. IQVIA Holdings Inc. has a twelve month low of $135.97 and a twelve month high of $252.88. The stock has a market cap of $27.05 billion, a price-to-earnings ratio of 20.46, a P/E/G ratio of 1.99 and a beta of 1.46. The business has a fifty day moving average of $168.27 and a 200-day moving average of $191.90.

IQVIA (NYSE:IQV - Get Free Report) last posted its quarterly earnings data on Thursday, February 6th. The medical research company reported $2.90 earnings per share for the quarter, missing analysts' consensus estimates of $3.11 by ($0.21). IQVIA had a net margin of 8.91% and a return on equity of 28.81%. As a group, equities research analysts anticipate that IQVIA Holdings Inc. will post 10.84 EPS for the current year.

Analysts Set New Price Targets

A number of research analysts have commented on the company. Barclays restated an "equal weight" rating and set a $170.00 price target (down from $235.00) on shares of IQVIA in a research note on Thursday, April 10th. Citigroup lowered their target price on IQVIA from $225.00 to $210.00 and set a "neutral" rating for the company in a report on Tuesday, March 4th. Royal Bank of Canada reiterated an "outperform" rating and set a $270.00 price target on shares of IQVIA in a research note on Monday, February 10th. UBS Group dropped their price objective on shares of IQVIA from $260.00 to $255.00 and set a "buy" rating for the company in a report on Friday, February 7th. Finally, Stifel Nicolaus reduced their target price on shares of IQVIA from $273.00 to $261.00 and set a "buy" rating on the stock in a report on Friday, February 7th. Eight investment analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average price target of $237.62.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.